PMID- 21486631
OWN - NLM
STAT- MEDLINE
DCOM- 20110729
LR  - 20110413
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 43
IP  - 3
DP  - 2011 Apr
TI  - Long-term results of autologous stem cell transplantation in the treatment of 
      patients with congestive heart failure.
PG  - 931-4
LID - 10.1016/j.transproceed.2011.01.115 [doi]
AB  - BACKGROUND: The aim of this study was to assess the long-term efficacy of stem 
      cell transplantation with revascularization for patients with ischemic 
      cardiomyopathy. METHODS: We enrolled 17 patients with ischemic cardiomyopathy who 
      had undergone autologous stem cell treatment. To assess myocardial ischemia and 
      viability they underwent coronary angiography, stress tests with dobutamine, 
      echocardiography, and positron emission tomography. Peripheral stem cells 
      mobilized using granulocyte colony-stimulating factor (G-CSF) were collected by 
      aphseresis for transplantation transmyocardially into the areas of injury during 
      coronary artery bypass surgery to increase blood flow to the engrafted areas. 
      RESULTS: Three patients died in the early follow-up period and 4 patients with 
      cardiac failure died during mid-term follow-up; they all underwent stem cell 
      transplantation at 6 months after acute myocardial infarction. The mean follow-up 
      period of the remaining 10 patients was 85.8 +/- 9.2 months (range, 70-100). Mean 
      left ventricular ejection fraction improved to 30.0 +/- 6.7, whereas the 
      preoperative mean left ventricular ejection fraction of the surviving patients 
      was 25.6 +/- 4.5 (P = .035). Mean New York Heart Association (NYHA) functional 
      class decreased from 3.2 to 1.5 (P = .006). When the study population was divided 
      into 2 subgroups according to the interval between acute myocardial infraction 
      and surgery, the patients who underwent autologous stem cell transplantation 
      within the first 6 months after myocardial infraction (Group 1) showed 
      significantly lower NYHA scores at the last follow-up (P = .024 in Group 1 and P 
      = .102 in Group 2). No side effects were observed to be due to the stem cell or 
      G-CSF injections. CONCLUSION: Treatment of ischemic cardiomyopathy with 
      autologous stem cell transplantation is easy and safe, opening a new window in 
      the treatment of "no hope" patients.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Oguz, E
AU  - Oguz E
AD  - Department of Cardiovascular Surgery, Ege University Medical Faculty, Izmir, 
      Turkey. emroguz@hotmail.com
FAU - Ayik, F
AU  - Ayik F
FAU - Ozturk, P
AU  - Ozturk P
FAU - Engin, C
AU  - Engin C
FAU - Nalbantgil, S
AU  - Nalbantgil S
FAU - Yagdi, T
AU  - Yagdi T
FAU - Ozbaran, M
AU  - Ozbaran M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Coronary Artery Bypass
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*surgery
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2011/04/14 06:00
MHDA- 2011/07/30 06:00
CRDT- 2011/04/14 06:00
PHST- 2011/04/14 06:00 [entrez]
PHST- 2011/04/14 06:00 [pubmed]
PHST- 2011/07/30 06:00 [medline]
AID - S0041-1345(11)00199-0 [pii]
AID - 10.1016/j.transproceed.2011.01.115 [doi]
PST - ppublish
SO  - Transplant Proc. 2011 Apr;43(3):931-4. doi: 10.1016/j.transproceed.2011.01.115.